Abstract: Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, tautomer, prodrug or stereoisomer thereof, wherein R1, R2a, R3a, R3b, R4a, R4b, G1, G2, L1, L2, m1, m2, A, B, W, X, Y, Z and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.

Abstract: Disclosed are chimeric antigen receptors (CARs), comprising an antigen binding domain, a transmembrane domain; a costimulatory domain; and a signaling domain comprising one of a CD3? signaling domain, a CD3? signaling domain, a CD3? signaling domain, or a DAP12 signaling domain. Disclosed is a nucleic acid encoding a CAR and recombinant vector comprising such nucleic acids. Disclosed is a host cell comprising such nucleic acids and recombinant vectors, and a pharmaceutical composition comprising such host cells. Disclosed is method of treating disease in a patient in need of thereof, or inducing an immune response in a subject or immunizing a subject against a cancer.

Abstract: Provided in the embodiments of the present disclosure are a method and device for processing a data packet, a storage medium, and an electronic device. The method includes: in a case where a Bit-Forwarding Ingress Router (BFIR) performs Bit Index Explicit Replication (BIER) packet encapsulation and outer Internet Protocol Version 6 (IPv6) packet encapsulation on a data packet, copying an Entropy field in a BIER packet header to a position of a Flow Label field of an outer IPv6 packet, and placing a label value allocated for Virtual Private Network (VPN) data in a position of the original Entropy field in the BIER packet header; and setting a data packet after the BIER packet header, and setting a Proto field in the BIER packet header to a corresponding value indicating a data packet type of the data packet.

Abstract: A displaying method and apparatus for application performance management are disclosed. The method includes obtaining data from a target application; mapping the data into a plurality of dimensions; displaying a plurality of layers corresponding to the plurality of dimensions; and displaying, based on a dimension associated with an object supported by the target application, a visualized node corresponding to the object at a corresponding layer of the plurality of layers.

Abstract: A light reflection assembly includes a reflection element, a substrate, a first cantilever beam, a second cantilever beam, a magnetic structure, and a support structure. The substrate is located on the magnetic structure, the reflection element is located in a hollow region in the middle of the substrate. Two ends of the reflection element are connected to the substrate through the first cantilever beam and the second cantilever beam, respectively. The first cantilever beam and second cantilever beam are located on different sides of the reflection element and are disposed along a first axial direction. A front side of the reflection element is configured to reflect incident light. The magnetic structure is configured to drive the reflection element to rotate. The support structure is fastened to the magnetic structure. An end of the support structure is in contact with a back side of the reflection element.

Abstract: According to one embodiment, an adjustable power capacity Power Supply Unit (PSU) includes a circuit coupled within a feedback loop of the PSU that is controlled by an internal processing system. The feedback loop configured to carry a feedback signal for regulating an output power of the PSU. The processing system includes executable instructions that may be executed to receive an output power capacity set point that represents a programmed output power rating of the PSU, and control the circuit to modify the feedback signal so that the PSU generates output power at the programmed output power rating. The programmed output power rating set on the PSU being less than an actual output power rating of the PSU.

Abstract: An automatic focus apparatus for a camera module includes a voice coil motor and a driving unit. The voice coil motor includes a frame, a moving member with a lens, and a magnetic member. The magnetic member is positioned at a side wall of the moving member, the driving unit is positioned at a side plate of the frame. A magnetic field is generated by the driving unit and the magnetic member, the magnetic field drives the moving member with the lens to move, to achieve automatic focus.

Abstract: The present disclosure discloses a method for liquid fermentation of black tea juice by using aged green tea and belongs to the technical field of tea leaf processing. The method comprises the following process steps: mixing aged green tea with hot water for a water bath-assisted extraction; adding a tannase into a crude catechin extract for a water bath-assisted enzymolysis; freeze-withering fresh tea leaves; homogenizing the freeze-withered leaves; pouring a homogenate into a primarily enzymolyzed crude catechin extract, adding a ?-glucosidase for secondary enzymolysis and performing fermentation; and treating a fermentation broth by microwave, and performing filtration and cooling to a room temperature.

Abstract: Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, tautomer, prodrug or stereoisomer thereof, wherein R1, R2a, R3a, R3b, R4a, R4b, G1, G2, L1, L2, m1, m2, A, B, W, X, Y, Z and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.

Abstract: Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, stereoisomer, isotopic form or prodrug thereof, wherein R1, R2a, R2b, R2c, R3a, R3b, R4a, R4b, R5, L1, L2, L3, E, m1, m2 and * are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.

Abstract: A compound of Formula (I) is provided: (I) where the variables are defined herein.

Abstract: An LED light bulb comprising a lamp housing, a bulb base, connected to the lamp housing, a stem connected to the bulb base and located in the lamp housing; an LED filament, disposed in the lamp housing, where points of the LED filament in an xyz coordinates are defined as x, y, and z, an x-y plane of the xyz coordinates is perpendicular to the height direction of the LED light bulb, an z-axis of xyz coordinates is parallel with the stem, and the projection of the LED filament on the x-y plane, y-z plane and x-z plane respectively has a length L1, L2 and L3, and the length L1, the length L2, and the length L3 are substantially in a ratio of 1:(0.5 to 1):(0.6 to 0.9).

Abstract: A reflector (10), a method for manufacturing the same, a lens module (001), and an electronic device are provided, and pertain to the field of optical technologies. The reflector (10) uses a silicon-based substrate (101) with a planar structure as a base material, which can effectively reduce a volume and mass of the reflector (10) when compared with a right triangular prism. In addition, an included angle (?) between a second side surface (1d) and a second surface (1b) of the silicon-based substrate (101) is designed as an obtuse angle, to ensure that after the reflector (10) is arranged in an inclined manner, a right angle protruding outward is not formed between the second side face (1d) and the second surface (1b).

Abstract: Compounds with KRAS G12C inhibitory active are disclosed and methods of using the same to treat a cancer comprising a K-Ras G12C mutation.

Abstract: Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein A, B, E, L1, Ra. Rb, Rc and are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.

Abstract: Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, stereoisomer, isotopic form or prodrug thereof, wherein R1, R2a, R2b, R2c, R3a, R3b, R4a, R4b, R5, L1, L2, E, m1 and m2 are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.

Abstract: The present disclosure provides a packet encapsulation method, including: determining a segment routing-traffic engineering (SR-TE) path; generating, according to a segment identifier (SID) of each node in the SR-TE path, an SID list, where each node supports a plurality of unified-SID encapsulation types (UETs) corresponding to SIDs of different lengths, and in the SID list, the SID of at least a node serving as an intermediate node of the SR-TE path is the SID having the non-longest length in the plurality of SIDs corresponding to the node; forming a segment routing header (SRH) from the SID list; and encapsulating an initial packet with the SRH to obtain a final packet. The present disclosure further provides a packet forwarding method, a UET announcement method, an electronic device, and a computer-readable storage medium. The final packet obtained by the packet encapsulation method has a higher load rate.

Abstract: Compounds with KRAS G12C inhibitory active are disclosed and methods of using the same to treat a cancer comprising a K-Ras G12C mutation.

Abstract: Described herein are small molecule splicing modulator compounds that modulate splicing of mRNA, such as pre-mRNA, encoded by genes, pharmaceutical compositions comprising the same, and methods of use of the small molecule splicing modulator compounds for modulating splicing and treating diseases and conditions.

Abstract: The present disclosure relates to a crystal form of a pyridopyrimidine derivative and a preparation method thereof, and specifically relates to the crystal form of the compound of formula (I) and a preparation method thereof. The new crystal form has good physical and chemical properties, thereby facilitating clinical treatments.